David Weingeist
Senior Scientific Director, Global Oncology Diagnostics Leader Johnson & Johnson
David Weingeist is Senior Scientific Director, Global Oncology Diagnostics Leader at Johnson & Johnson Innovative Medicine, a role held since May 2026. Previously, he was Director, BioPharma Global Commercial Strategy Leader at Foundation Medicine, and held roles at Genentech, ZS and Simon-Kucher & Partners. He holds a PhD in Biological Engineering from MIT and an MPhil in BioScience Enterprise from the University of Cambridge.
Seminars
Thursday 18th March 2027
Moving MRD from a Prognostic Signal to a Decision-Making Diagnostic: Lessons from Bladder Cancer
11:30 am
- Breaking down the MRD label into distinct intended uses, and why each demands a different level of proof
- Defining the clinical decision points where MRD results change what happens to the patient
- Applying that framework to bladder cancer, including early learnings from a urinebased MRD application
- Assessing what regulators will need to see before MRD-guided decisions become standard of care, and what the first companion diagnostic signals for the field
Friday 19th March 2027
Panel Discussion: Translating the Multiple Myeloma Endpoint Precedent into Solid Tumor Programs to Shorten the Path to Regulatory Acceptance
12:00 pm
- Unpacking what secured MRD acceptance in myeloma and which elements transfer to solid tumors
- Addressing the sensitivity and heterogeneity challenges that make the solid tumor case fundamentally harder
- Sequencing the evidence generation so indications build on each other rather than starting from zero
